Navigation Links
Champions Oncology Reports Full Year 2011 Financial Results
Date:7/15/2011

s of the original human tumor.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Services ("POS") in which physicians and patients looking for information to help guide the development of personalized treatment plans, and Translational Oncology Services ("TOS") in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increase the adoption of existing drugs. The Company's Tumorgraft Technology Platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs.  The Company is building its Tumorgraft Technology Platform through the procurement, development and characterization of numerous Tumorgrafts (within several cancer types).  Tumorgrafts are procured through agreements with a number of U.S. and foreign institutions as well as through the Company's  POS business.  The Tumorgrafts are developed and tested through agreement with a U.S. based pre-clinical facility.

The Company provides Personalized Oncology Solutions services to oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients' cancer tissues, as appropriate.  Additionally, the Company offers personalized Tumorgraft development, drug studies and genome sequencing as part of its POS whereby physicians can evaluate the effects of cancer drugs on their patients' Tumorgrafts and understand the genetic make-up of their patient's tumor enabling them to better select treatment regimens that may be efficacious to the patient.

This press release contains "forward-looking statements" (within the m
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
2. Champions Biotechnology Changes Name to Champions Oncology
3. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
4. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
5. Champions Biotechnology Reports Additions to its Management Team
6. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
8. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
9. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
10. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
11. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 BioClinica®, Inc., a leading provider of ... three of its experts are speaking at the ... to be held September 28 to October 1 in ... also announced the innovative Compass technology, a ... trials acquired earlier this year, is up for the ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
(Date:9/17/2014)... LAKE FOREST, California , 17 de ... BB: CYRX) ("la compañía"), principal proveedor mundial ... industria de las ciencias de la vida, ... una compañía de logística global con sede ... a su base de clientes Europa en ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5
... - Teva Announces Sufficient Funds to Complete Acquisition, ... Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) and Barr,Pharmaceuticals, ... and its,syndicate of lending banks, arranged by Bank of ... permit them to remain in place,following Barr,s acquisition by ...
... call today at 4:30 p.m. ET -, SOUTH ... MGRM ) today reported financial results for the,quarter ... of $16.1 million for the third quarter of,2008, 55% ... 2007. This,growth was driven by revenue from Trofile(TM) for ...
... Calif., Oct. 27 Abaxis, Inc.,(Nasdaq: ABAX ), ... reported financial results for the fiscal,quarter ended September 30, ... of $27.7 million, up 10% over last year,s comparable,quarter., ... 17% over last year,s,comparable quarter., -- Record medical ...
Cached Biology Technology:Teva and Barr Provide Update on Acquisition 2Teva and Barr Provide Update on Acquisition 3Teva and Barr Provide Update on Acquisition 4Teva and Barr Provide Update on Acquisition 5Monogram Announces 2008 Third Quarter Financial Results 2Monogram Announces 2008 Third Quarter Financial Results 3Monogram Announces 2008 Third Quarter Financial Results 4Monogram Announces 2008 Third Quarter Financial Results 5Monogram Announces 2008 Third Quarter Financial Results 6Monogram Announces 2008 Third Quarter Financial Results 7Monogram Announces 2008 Third Quarter Financial Results 8Monogram Announces 2008 Third Quarter Financial Results 9Monogram Announces 2008 Third Quarter Financial Results 10Monogram Announces 2008 Third Quarter Financial Results 11Monogram Announces 2008 Third Quarter Financial Results 12Monogram Announces 2008 Third Quarter Financial Results 13Monogram Announces 2008 Third Quarter Financial Results 14Monogram Announces 2008 Third Quarter Financial Results 15Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 2Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 3Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 4Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 5Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 6Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 7Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 8Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009 9
(Date:9/17/2014)... has learned a great deal about complex social behavior ... have something to teach too. , With their unusually ... cognition, parrots live in a complex social environment---not merely ... bees or ants, but in a dynamic setting of ... most intelligent mammals: dolphins, whales, primates, and social carnivores, ...
(Date:9/16/2014)... morbidity amongst women in Australia is increased by ... today (17 September) in BJOG: An International ... generally enjoy high standards of living; however, existing ... particular between indigenous and non indigenous Australians. , ... impact of socioeconomic position on severe maternal morbidities ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... increase the likelihood of immune complications following bone marrow ... November 22 advance online issue of Nature Genetics ... the donor,s genome but present in the recipient,s, transplants ... known as graft-versus-host disease, in which immune cells from ...
... and technological frontiers. The National Science Foundation has recently ... diverse efforts of the following investigators under the American ... researchers have been awarded grants for investigation of solar ... enhance the capabilities of NJIT,s Big Bear Solar Observatory ...
... to contribute their abstracts to the World Congress on ... meeting devoted to all aspects of osteoporosis and osteoarthritis ... in Florence, Italy from May 5-8, 2010. Beginning ... The submission deadline is February 4, ...
Cached Biology News:Gene mismatch influences success of bone marrow transplants 2Gene mismatch influences success of bone marrow transplants 3Gene mismatch influences success of bone marrow transplants 4NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3
...
Request Info...
... Partially purified chicken intestinal cytoplasmic 1,25-(OH)2D3 ... receptor (VDR) from human, rat, mouse, ... This antibody does not cross-react ... MA1-710 detects both the occupied and ...
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
Biology Products: